1. P791: COMMON VARIANTS IN COMPLEMENT PROTEINS, C3 AND CR1, ENHANCE COMPLEMENT ATTACK ON PNH ERYTHROCYTES AND INCREASE RISK FOR EXTRAVASCULAR HAEMOLYSIS. (23rd June 2022) Authors: Baral, A. J.; Mckinley, C.; Fellows, R.; Hallam, T.; Cox, T.; Payne, D.; Richards, S.; Pike, A.; Kelly, R.; Griffin, M.; Hillmen, P.; Marchbank, K.; Kavanagh, D.; Newton, D.; Harris, C. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 686 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Potential use of the PARP inhibitor rucaparib to enhance cervical cancer treatment. (October 2020) Authors: Saha, S.; Howarth, R.; Pappworth, I.; Marchbank, K.; Curtin, N. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S37 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. SP-0517: Increasing the therapeutic index of radiation by combination with rucaparib in cervical cancer. (November 2020) Authors: Saha, S.; Howarth, R.; Dubrovska, A.; Marchbank, K.; Curtin, N. Journal: Radiotherapy and oncology Issue: Volume 152(2020)Supplement 1 Page Start: S283 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗